🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesGLP-1 and peripheral arterial disease — looking for input Page 4

GLP-1 and peripheral arterial disease — looking for input

dan_philly Thu, Mar 21, 2024 at 8:07 PM 44 replies 3,088 viewsPage 4 of 9
MariaRD
Member
823
4,567
Jun 2024
New Mexico
Mar 25, 2024 at 6:06 AM#16
NurseKim_ATL said:
Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling,…

This is my experience too, for whatever a second data point is worth. Nothing to add that would improve it.

Last edited: Mar 25, 2024 at 7:06 AM
12 10Dr.NutriCornell, pam_stl, wei_SG and 9 others
Reply Quote Save Share Report
lucas_SP_BR
Member
456
1,890
Jun 2024
São Paulo, BR
Mar 25, 2024 at 2:56 PM#17
PeptideSynthNJ said:
dan_philly said: ...we're creating a generation dependent on cardiovascular risk...

Metabolic syndrome resolution on cardiovascular risk: I went from meeting 5 of 5 diagnostic criteria to meeting ZERO after 13 months of treatment.

The 5 criteria (and my journey):

  1. Waist circumference: 52" → 34" ✅ Resolved
  2. Triglycerides: 260 → 100 ✅ Resolved
  3. HDL: 36 → 52 ✅ Resolved
  4. Blood pressure: 140/90 → 118/72 ✅ Resolved
  5. Fasting glucose: 125 → 88 ✅ Resolved

Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.

13 11Dr.ObesityLA, NurseKim_ATL, paul_denver and 10 others
Reply Quote Save Share Report
rachel_ABQ
Member
178
890
Dec 2024
Albuquerque, NM
Mar 25, 2024 at 11:46 PM#18

A narrower follow-up, since the general answer is now clear:

How long did you give it before you decided it was working?

14 12AmyNC_wife, SkepticalSean, Dr.CardioMD and 11 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
Dr.SurgeonPGH
Senior Member
1,345
6,789
Mar 2024
Pittsburgh, PA
Mar 26, 2024 at 8:36 AM#19
lucas_SP_BR said:
Metabolic syndrome resolution on cardiovascular risk: I went from meeting 5 of 5 diagnostic criteria to meeting ZERO after 13 months of treatment.

Positive "side effect" of cardiovascular risk: my blood pressure dropped so much that I'm now off lisinopril entirely! My cardiologist is thrilled.

If you're on BP meds and losing weight on a GLP-1, monitor your BP at home regularly. Hypotension symptoms (dizziness, lightheadedness when standing) mean your BP meds may need reduction. Don't wait for your next scheduled appointment — call your doctor.

15 13RickReta_CO, PharmHunterJen, TomTeleRx and 12 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Mar 26, 2024 at 5:26 PM#20

Moderator note: a couple of off-topic posts removed. Tagging this one for the weekly digest.

37 10PurityPaulOR, MaxMetOK, MounjBrad and 34 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register